Targeting ALK in Neuroendocrine Tumors of the Lung

BackgroundAnaplastic lymphoma kinase (ALK) rearrangements are known oncogenic drivers in non-small cell lung cancer (NSCLC). Few case reports described the occurrence of such rearrangements in large cell neuroendocrine carcinomas (LCNECs) of the lung without information on clinical responses to ALK...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Dilara Akhoundova, Martina Haberecker, Ralph Fritsch, Sylvia Höller, Michael K. Kiessling, Markus Rechsteiner, Jan H. Rüschoff, Alessandra Curioni-Fontecedro
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-06-01
Subjects:	ALK rearrangements neuroendocrine tumors of the lung large cell neuroendocrine carcinoma ALK inhibitors targeted treatment
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.911294/full